Loading grant details…
Targeting EBV-associated lymphomas
| Funder | NATIONAL CANCER INSTITUTE |
|---|---|
| Recipient Organization | University of North Carolina Chapel Hill |
| Country | United States |
| Start Date | Sep 10, 2024 |
| End Date | Aug 31, 2029 |
| Duration | 1,816 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 11001649 |
Grant Description
ABSTRACT Epstein-Barr Virus (EBV) is the etiological agent of several hematopoietic malignancies including multiple types of non-Hodgkin lymphoma (NHL). These EBV-positive NHL subtypes are comprised of post-transplant lymphoproliferative disease (PTLD), diffuse large B cell lymphomas (DLBCL), T cell lymphomas, Natural killer
(NK)/T cell lymphoma (NKTL), and Burkitt's lymphoma (BL). Our studies have found that FAM72A is highly expressed in EBV-positive lymphomas and contributes to EBV-mediated lymphomagenesis, which gives rise to EBV-positive NHL. In response to PAR-21-348, we propose to address how EBV’s upregulation of FAM72A
contributes to the development of EBV-driven NHL.
All Grantees
University of North Carolina Chapel Hill
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Related Grants
